Immunotherapeutics for head and neck squamous cell carcinoma stem cells

X. Qian, F. Leonard, Y. Wenhao, H. Sudhoff, T. K. Hoffmann, S. Ferrone, A. M. Kaufmann, A. E. Albers

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Cancer stem cell (CSC)-related therapy resistance has become a new obstacle to the successful application of cancer treatment and head and neck squamous cell carcinoma (HNSCC) is no exception to this finding. Head and neck squamous cell carcinoma is highly immune-suppressive, and recently the immune suppression and invasion of HNSCC-CSCs have been characterized. These characteristics have received research and clinical attention because they would enable the stratification of patients into specific cancer subtypes and, consequently, the establishment of new therapeutic approaches with improved efficacy. This review discusses the feasibility of CSC-targeted strategies and their incorporation with nanotechnology to improve the efficacy of cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)94-99
Number of pages6
Issue number2
StatePublished - Feb 1 2020


  • Cancer nanomedicine
  • Cancer stem cell
  • Cancer vaccine
  • Immunotherapy
  • Nanotechnology
  • Humans
  • Cell Line, Tumor
  • Neoplastic Stem Cells
  • Head and Neck Neoplasms/therapy
  • Squamous Cell Carcinoma of Head and Neck/therapy

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Immunotherapeutics for head and neck squamous cell carcinoma stem cells'. Together they form a unique fingerprint.

Cite this